RT Journal Article
SR Electronic
T1 Molecular Characterization of Colorectal Cancers
JF American Society for Clinical Laboratory Science
JO Clin Lab Sci
FD American Society of Chemistry and Laboratory Science
DO 10.29074/ascls.2022003208
A1 Lewis, Sally
A1 Telgenhoff, Dale
A1 Dubansky, Brooke
YR 2024
UL http://hwmaint.clsjournal.ascls.org/content/early/2024/10/16/ascls.2022003208.abstract
AB Characterization of the molecular mutations in colorectal cancers has made great progress since the initial report by Fearon and Vogelstein describing a series of histologic changes that correlate to a series of mutations. Since 1990, numerous mutational pathways have been associated with 1 or more actionable targets leading to more precise treatments in the development of colorectal cancers, including inherited and sporadic ones. The accumulation of mutations leads to the acquisition of cancer-promoting qualities such as increased cellular proliferation, immune evasion, and resistance to apoptosis. Mutations of tumor suppressor and protooncogenes such as KRAS and BRAF have an important role in the prognosis and therapeutic selection of treatment. Broadening the use of multigene next-generation sequencing panels in patients with colorectal cancer may allow earlier identification of more actionable targets in patients, providing more precise treatments.